Company: PFSA
Filing Date: 2025-08-22
Form Type: S-1/A
Source: 0001213900-25-079829
Chunk: 24

Company: Profusa, Inc.
Filing Date: 2025-08-22
Form: S-1/A
Chunk 24
---
ee Oxygen Platform; and •expansion of our workforce. We expect our research and development expenses to increase in connection with our continued clinical trials and other development activities related to our products. We also expect that our general and administrative expenses will continue to increase due, among other things, to our expansion of commercialization for the Lumee Oxygen and Glucose Platform and the additional operational and regulatory burdens applicable to public healthcare and medical device companies. As a result, we will likely continue to incur operating losses in the future. These losses, among other things, may have an adverse effect on our stockholders’ equity. 12 We may need to raise additional funding to expand the commercialization of our products and services and to expand our research and development efforts. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization or development efforts or other operations. Our operations have consumed substantial amounts of cash since inception. We expect to expend substantial additional amounts to commercialize our products and services and to develop new products and services. We expect to use the funds received in connection with the Business Combination to scale our operations, develop new products and services, expand internationally, and for working capital and general corporate purposes. We may require additional capital to conduct clinical trials, expand the commercialization of our existing product and services and to develop new products and services. In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. The amount of funding we may need will depend on many factors, including: •the revenue generated by our products; •the costs, timing and risks of delay of regulatory approvals; •the expenses we incur in manufacturing, developing, selling and marketing our products; •our ability to scale our manufacturing operations to meet demand for our current and any future products; •the costs to produce our continuous glucose monitoring systems; •the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; •the rate of progress and cost of our clinical trials and other development activities; •the success of our research and development efforts; •the emergence of competing or complementary technologies; •the terms and timing of any collaborative, licensing and other arrangements that we may establish; •the cost of ongoing compliance with legal and regulatory requirements, and third -partypayors’ policies; •the cost of obtaining and maintaining regulatory or payor